Clinical Trial Update: Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating tocilizumab as add-on therapy for residual positive, negative, and cognitive symptoms in schizophrenia and schizoaffective dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 4 | Status: COMPLETED | Results posted: 2018-12-26